New compounds for tailored therapy against MLL-rearranged leukaemia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/630621

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Some of the worst leukaemia survival rates are found in children and adults whose leukaemias display abnormalities of the MLL gene and alternative therapies are therefore urgently required for these patients. The aim of this project is to develop new compounds that specifically inhibit this abnormal gene and in turn inhibit the growth of these cells in the patient. In this way we hope to provide new and more effective therapies for patients affected with this aggressive type of leukaemia.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $326,401.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Molecular Targets

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Leukaemia | Oncogene | Paediatric oncology | acute lymphoblastic leukaemia | drug resistant leukaemia | myeloid leukaemia | novel therapeutic | targeted therapy

Related Links